ω-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study

December 2009
American Journal of Clinical Nutrition;Dec2009, Vol. 90 Issue 6, p1601
Academic Journal
The article presents the Age-Related Eye Disease Study (AREDS), a phase 3 clinical trial on long-chain polyunsaturated fatty acid intake and 12-year incidence of neovascular age-related macular degeneration and central geographic atrophy. It notes that the AREDS was designed to evaluate the clinical course, prognosis, risk factors, and nutrient-based treatments of age-related macular degeneration (AMD). Objective and design of the study are discussed.


Related Articles

  • Reducing the Risk of Vision Loss.  // Ophthalmology Times;1/15/2005 Supplement, Vol. 30, p5 

    The article presents information about preventing vision loss. The article suggests the use of supplements and dietary changes. According to Age-Related Eye Disease Study, antioxidant-mineral supplementation can significantly decrease the progression to a more advanced stage. There is also...

  • An Early Look At AREDS2. Gunvant, Pinakin; Jennings, Barbara; Vyas, Darshna // Review of Optometry;4/15/2011, Vol. 148 Issue 4, p59 

    The article provides a preliminary overview of the goals and nutrient formulations of the Age-Related Eye Disease Study or AREDS2 in the practice of optometry in the U.S. It reviews and compares both the original AREDS and AREDS2 and evaluates how results from both studies impacted the...

  • Dietary n-3 PUFA Vascular Targeting and the Prevention of Tumor Growth and Age-Related Macular Degeneration. Serini, S.; Piccioni, E.; Calviello, G. // Current Medicinal Chemistry;Dec2009, Vol. 16 Issue 34, p4511 

    The protective role of dietary n-3 polyunsaturated fatty acids (PUFAs) against cardiovascular diseases has been partly related to their ability to modulate the risk condition known as "endothelial dysfunction", by reverting the endothelial alterations associated to it (reduced vascular...

  • Anecortave acetate endpoint not met but results similar to PDT. Charters, Lynda // Ophthalmology Times;11/15/2004, Vol. 29 Issue 22, p37 

    This article reports that the C-01-99 phase III clinical trial of anecortave acetate for depot suspension found that the drug did not meet the primary endpoint of non-inferiority to verteporfin in the treatment of neovascular age-related macular degeneration. In the phase III prospective,...

  • Retaane: Targeting Multiple Factors. Slakter, Jason S. // Review of Ophthalmology;Dec2005, Vol. 12 Issue 12, Special section p12 

    The article presents information on the mechanism of action and delivery method specific to retaane together with the results of the recent clinical trials. The age-related mascular degeneration is a continuous process that involves neovascularization. In this process the growth of vascular...

  • Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis. Das, Undurti N. // Current Nutrition & Food Science;2009, Vol. 5 Issue 2, p94 

    Diabetic retinopathy and age-related macular degeneration (AMD) are due to neovascularization as a result of increased production of growth hormone, insulin-like growth factor (IGF), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β), hepatocyte growth factor,...

  • DNA Sequence Variants in PPARGC1A, a Gene Encoding a Coactivator of the &omega-3 LCPUFA Sensing PPAR-RXR Transcription Complex, Are Associated with NV AMD and AMD-Associated Loci in Genes of Complement and VEGF Signaling Pathways. SanGiovanni, John Paul; Jing Chen; Sapieha, Przemyslaw; Aderman, Christopher M.; Stahl, Andreas; Clemons, Traci E.; Chew, Emily Y.; Smith, Lois E. H. // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Background: Increased intake of v-3 long-chain polyunsaturated fatty acids (LCPUFAs) and use of peroxisome proliferator activator receptor (PPAR)-activating drugs are associated with attenuation of pathologic retinal angiogenesis. v-3 LCPUFAs are endogenous agonists of PPARs. We postulated that...

  • CNV development in fellow eye more active after first year of anti-VEGF treatment. Mullin, David W.; Nale, Patricia // Primary Care Optometry News;Jul2012, Vol. 17 Issue 7, p9 

    The article reports on the claim by Doctor Maureen G. Maguire that based on a 2-year data, more fellow eyes of patients culled from the Complications of Age-Related Macular Degeneration Treatment Trials (CATT) developed choroidal neovascularization in the second year of follow-up than the first.

  • Studies to determine if others may benefit from PDT. Talsma, Julia // Ophthalmology Times;2/15/2002, Vol. 27 Issue 4, p10 

    Highlights several clinical trials aimed at expanding the benefits of photodynamic therapy (PDT) for patients with subfoveal choroidal neovascularization (CNV) in age-related macular degeneration. Results of the PDT with verteporfin trial; Rationale of the Visudyne In Minimally Classic CNV...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics